Clinical Trial Update: A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study of Firi-cel for relapsed/refractory diffuse large B-cell lymphoma has terminated; sponsor CARGO Therapeutics provided the status update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Firi-cel

Snippet

Sponsor: CARGO Therapeutics | Conditions: Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Status: TERMINATED